189 related articles for article (PubMed ID: 24745685)
41. Current state of biology and diagnosis of clonal mast cell diseases in adults.
Alvarez-Twose I; Morgado JM; Sánchez-Muñoz L; García-Montero A; Mollejo M; Orfao A; Escribano L
Int J Lab Hematol; 2012 Oct; 34(5):445-60. PubMed ID: 22551157
[TBL] [Abstract][Full Text] [Related]
42. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
Gotlib J; Akin C
Semin Hematol; 2012 Apr; 49(2):128-37. PubMed ID: 22449623
[TBL] [Abstract][Full Text] [Related]
43. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
[TBL] [Abstract][Full Text] [Related]
44. Treatment of systemic mast cell disorders.
Worobec AS
Hematol Oncol Clin North Am; 2000 Jun; 14(3):659-87, vii. PubMed ID: 10909045
[TBL] [Abstract][Full Text] [Related]
45. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
46. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).
Pardanani A
Blood; 2013 Apr; 121(16):3085-94. PubMed ID: 23426950
[TBL] [Abstract][Full Text] [Related]
47. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
48. The Role of KIT Mutations in Anaphylaxis.
Coulson E; Zhou S; Akin C
Curr Allergy Asthma Rep; 2019 Apr; 19(6):31. PubMed ID: 31028494
[TBL] [Abstract][Full Text] [Related]
49. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
50. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.
Molderings GJ; Brettner S; Homann J; Afrin LB
J Hematol Oncol; 2011 Mar; 4():10. PubMed ID: 21418662
[TBL] [Abstract][Full Text] [Related]
51. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.
Molderings GJ; Raithel M; Kratz F; Azemar M; Haenisch B; Harzer S; Homann J
Intern Med; 2011; 50(6):611-5. PubMed ID: 21422688
[TBL] [Abstract][Full Text] [Related]
52. [Mast cell activation syndrome].
Brockow K
Hautarzt; 2013 Feb; 64(2):102-6. PubMed ID: 23385621
[TBL] [Abstract][Full Text] [Related]
53. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Gotlib J; Gerds AT; Bose P; Castells MC; Deininger MW; Gojo I; Gundabolu K; Hobbs G; Jamieson C; McMahon B; Mohan SR; Oehler V; Oh S; Padron E; Pancari P; Papadantonakis N; Pardanani A; Podoltsev N; Rampal R; Ranheim E; Rein L; Snyder DS; Stein BL; Talpaz M; Thota S; Wadleigh M; Walsh K; Bergman MA; Sundar H
J Natl Compr Canc Netw; 2018 Dec; 16(12):1500-1537. PubMed ID: 30545997
[TBL] [Abstract][Full Text] [Related]
54. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
55. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
Ma Y; Zeng S; Metcalfe DD; Akin C; Dimitrijevic S; Butterfield JH; McMahon G; Longley BJ
Blood; 2002 Mar; 99(5):1741-4. PubMed ID: 11861291
[TBL] [Abstract][Full Text] [Related]
56. Mastocytosis: update on pharmacotherapy and future directions.
Cardet JC; Akin C; Lee MJ
Expert Opin Pharmacother; 2013 Oct; 14(15):2033-45. PubMed ID: 24044484
[TBL] [Abstract][Full Text] [Related]
57. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.
Jagdis A; Vadas P
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):115-6. PubMed ID: 24950847
[No Abstract] [Full Text] [Related]
58. Molecular alterations underlying eosinophilic and mast cell malignancies.
Sadrzadeh H; Abdel-Wahab O; Fathi AT
Discov Med; 2011 Dec; 12(67):481-93. PubMed ID: 22204765
[TBL] [Abstract][Full Text] [Related]
59. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
60. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior.
Büttner C; Henz BM; Welker P; Sepp NT; Grabbe J
J Invest Dermatol; 1998 Dec; 111(6):1227-31. PubMed ID: 9856847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
